KEAP1 and diabetes mellitus: A lipoprotein complex delivery system based on cationic lipid carrier DOTAP was used for transdermal delivery of siRNA targeting Kelch-like ECH-associated protein 1 (Keap1), which effectively inhibited the expression of NF-E2-related factor 2 (Nrf-2), and improved wound closure in a mouse model of diabetes [17].